Task_ID,Step_No,Task,Role,dispatch_date,O_Days,M_Days,P_Days,Use_PERT,Effort_Days,Notes,milestones
1,1,Management Decision ,Global Regulatory Lead,700,1,1,1,Y,0.3,Decision by senior management to proceed with the MAA preparation typically following positive Phase II results and regulatory interactions . This step confirms company commitment about 24 months before planned submission.,1
2,1,Management Decision ,Management,700,1,1,1,Y,0.3,Decision by senior management to proceed with the MAA preparation typically following positive Phase II results and regulatory interactions . This step confirms company commitment about 24 months before planned submission.,1
3,1,Management Decision ,Other function,700,1,1,1,Y,0.3,Decision by senior management to proceed with the MAA preparation typically following positive Phase II results and regulatory interactions . This step confirms company commitment about 24 months before planned submission.,1
4,1,Management Decision ,Regulatory CMC,700,1,1,1,Y,0.3,Decision by senior management to proceed with the MAA preparation typically following positive Phase II results and regulatory interactions . This step confirms company commitment about 24 months before planned submission.,1
5,2,Paediatric Investigation Plan (PIP),Regulatory Strategist (Global/EU),700,225,225,225,Y,70.0,Agreement of the Paediatric Investigation Plan (PIP) with the EMA a mandatory step to define the development strategy for paediatric use. Typically initiated early.,0
6,3,Paediatric Investigation Plan (PIP) agreed,EMA,475,1,1,1,Y,1.0,Agreement of the Paediatric Investigation Plan (PIP) with the EMA a mandatory step to define the development strategy for paediatric use. Typically initiated early.,1
7,4,General Kick-off meeting,Global Regulatory Lead,600,1,1,1,Y,0.3,Initial cross-functional meeting led by the Global Regulatory Lead to align all stakeholders on the MAA strategytimelines and deliverables. Usually held around 18 months before the planned submission to ensure coordinated planning across teams.,1
8,4,General Kick-off meeting,Labeling,600,1,1,1,Y,0.3,Initial cross-functional meeting led by the Global Regulatory Lead to align all stakeholders on the MAA strategytimelines and deliverables. Usually held around 18 months before the planned submission to ensure coordinated planning across teams.,1
9,4,General Kick-off meeting,Other function,600,1,1,1,Y,0.3,Initial cross-functional meeting led by the Global Regulatory Lead to align all stakeholders on the MAA strategytimelines and deliverables. Usually held around 18 months before the planned submission to ensure coordinated planning across teams.,1
10,4,General Kick-off meeting,Regulatory CMC,600,1,1,1,Y,0.3,Initial cross-functional meeting led by the Global Regulatory Lead to align all stakeholders on the MAA strategytimelines and deliverables. Usually held around 18 months before the planned submission to ensure coordinated planning across teams.,1
11,4,General Kick-off meeting,Regulatory Operations,600,1,1,1,Y,0.3,Initial cross-functional meeting led by the Global Regulatory Lead to align all stakeholders on the MAA strategytimelines and deliverables. Usually held around 18 months before the planned submission to ensure coordinated planning across teams.,1
12,4,General Kick-off meeting,Regulatory Strategist (Global/EU),600,1,1,1,Y,0.3,Initial cross-functional meeting led by the Global Regulatory Lead to align all stakeholders on the MAA strategytimelines and deliverables. Usually held around 18 months before the planned submission to ensure coordinated planning across teams.,1
13,5,Content Plan (documents list) prepared,Global Regulatory Lead,180,159,159,159,Y,2.8,Preparation of the detailed content plan listing all required CTD modules and documents aligned with the agreed regulatory strategy. This task ensures clarity on responsibilities timelines and EMA/CHMP interactions. Initiated at least 6 months before submission and maintained until finalization typically completed about 3 weeks before the MAA dispatch date.,0
15,5,Content Plan (documents list) prepared,Other function,180,159,159,159,Y,2.8,Preparation of the detailed content plan listing all required CTD modules and documents aligned with the agreed regulatory strategy. This task ensures clarity on responsibilities timelines and EMA/CHMP interactions. Initiated at least 6 months before submission and maintained until finalization typically completed about 3 weeks before the MAA dispatch date.,0
16,5,Content Plan (documents list) prepared,Regulatory CMC,180,159,159,159,Y,2.8,Preparation of the detailed content plan listing all required CTD modules and documents aligned with the agreed regulatory strategy. This task ensures clarity on responsibilities timelines and EMA/CHMP interactions. Initiated at least 6 months before submission and maintained until finalization typically completed about 3 weeks before the MAA dispatch date.,0
17,5,Content Plan (documents list) prepared,Regulatory Operations,180,159,159,159,Y,2.8,Preparation of the detailed content plan listing all required CTD modules and documents aligned with the agreed regulatory strategy. This task ensures clarity on responsibilities timelines and EMA/CHMP interactions. Initiated at least 6 months before submission and maintained until finalization typically completed about 3 weeks before the MAA dispatch date.,0
18,5,Content Plan (documents list) prepared,Regulatory Strategist (Global/EU),180,159,159,159,Y,2.8,Preparation of the detailed content plan listing all required CTD modules and documents aligned with the agreed regulatory strategy. This task ensures clarity on responsibilities timelines and EMA/CHMP interactions. Initiated at least 6 months before submission and maintained until finalization typically completed about 3 weeks before the MAA dispatch date.,0
19,6,Scientific advice / end of phase 2 meeting,Global Regulatory Lead,760,1,1,1,Y,0.2,Formal scientific advice meeting with EMA/CHMP at the end of Phase II to discuss clinical development regulatory expectations and submission strategy. Typically held 12–24 months before the planned MAA submission with ~18 months being the standard reference point.,1
20,6,Scientific advice / end of phase 2 meeting,Labeling,760,1,1,1,Y,0.2,Formal scientific advice meeting with EMA/CHMP at the end of Phase II to discuss clinical development regulatory expectations and submission strategy. Typically held 12–24 months before the planned MAA submission with ~18 months being the standard reference point.,1
21,6,Scientific advice / end of phase 2 meeting,Other function,760,1,1,1,Y,0.2,Formal scientific advice meeting with EMA/CHMP at the end of Phase II to discuss clinical development regulatory expectations and submission strategy. Typically held 12–24 months before the planned MAA submission with ~18 months being the standard reference point.,1
22,6,Scientific advice / end of phase 2 meeting,Regulatory CMC,760,1,1,1,Y,0.2,Formal scientific advice meeting with EMA/CHMP at the end of Phase II to discuss clinical development regulatory expectations and submission strategy. Typically held 12–24 months before the planned MAA submission with ~18 months being the standard reference point.,1
23,6,Scientific advice / end of phase 2 meeting,Regulatory Operations,760,1,1,1,Y,0.2,Formal scientific advice meeting with EMA/CHMP at the end of Phase II to discuss clinical development regulatory expectations and submission strategy. Typically held 12–24 months before the planned MAA submission with ~18 months being the standard reference point.,1
24,6,Scientific advice / end of phase 2 meeting,Regulatory Strategist (Global/EU),760,1,1,1,Y,0.2,Formal scientific advice meeting with EMA/CHMP at the end of Phase II to discuss clinical development regulatory expectations and submission strategy. Typically held 12–24 months before the planned MAA submission with ~18 months being the standard reference point.,1
47,12,Target Product Profile (TPP),Global Regulatory Lead,700,695,695,695,Y,12.0,Finalization of the Target Product Profile (TPP) a key strategic document that defines the intended indications clinical claims safety profile and regulatory positioning of the product. Developed cross-functionally and used as a decision-making reference. For EMA submissions it should be finalized between 12 and 6 months before submission with drafting initiated earlier and alignment reinforced around the end-of-Phase II meeting (~18 months before submission).,0
48,13,Centralised Procedure Eligibility Request,Global Regulatory Lead,130,60,75,90,Y,70.0,Submission of the eligibility request to EMA to confirm acceptance of the Centralised Procedure. This step ensures regulatory alignment on the chosen submission route and must be completed between 18 and 7 months before the planned MAA submission depending on project organization and availability of Phase II/III clinical data.,0
49,13,Centralised Procedure Eligibility Request,Labeling,130,60,75,90,Y,70.0,Submission of the eligibility request to EMA to confirm acceptance of the Centralised Procedure. This step ensures regulatory alignment on the chosen submission route and must be completed between 18 and 7 months before the planned MAA submission depending on project organization and availability of Phase II/III clinical data.,0
50,13,Centralised Procedure Eligibility Request,Regulatory CMC,130,60,75,90,Y,70.0,Submission of the eligibility request to EMA to confirm acceptance of the Centralised Procedure. This step ensures regulatory alignment on the chosen submission route and must be completed between 18 and 7 months before the planned MAA submission depending on project organization and availability of Phase II/III clinical data.,0
51,13,Centralised Procedure Eligibility Request,Regulatory Operations,130,60,75,90,Y,70.0,Submission of the eligibility request to EMA to confirm acceptance of the Centralised Procedure. This step ensures regulatory alignment on the chosen submission route and must be completed between 18 and 7 months before the planned MAA submission depending on project organization and availability of Phase II/III clinical data.,0
52,13,Centralised Procedure Eligibility Request,Regulatory Strategist (Global/EU),130,60,75,90,Y,75.0,Submission of the eligibility request to EMA to confirm acceptance of the Centralised Procedure. This step ensures regulatory alignment on the chosen submission route and must be completed between 18 and 7 months before the planned MAA submission depending on project organization and availability of Phase II/III clinical data.,0
53,14,Letter of Intent sent to EMA,Global Regulatory Lead,210,30,50,70,Y,30,Formal notification to the EMA of the company’s intention to submit a Marketing Authorisation Application (MAA) via the Centralised Procedure. This letter is typically sent around 7 months before the planned submission to allow EMA to plan resources and appoint rapporteurs.,0
54,14,Letter of Intent sent to EMA,Regulatory Operations,210,30,50,70,Y,30,Formal notification to the EMA of the company’s intention to submit a Marketing Authorisation Application (MAA) via the Centralised Procedure. This letter is typically sent around 7 months before the planned submission to allow EMA to plan resources and appoint rapporteurs.,0
55,14,Letter of Intent sent to EMA,Regulatory Strategist (Global/EU),210,30,50,70,Y,35,Formal notification to the EMA of the company’s intention to submit a Marketing Authorisation Application (MAA) via the Centralised Procedure. This letter is typically sent around 7 months before the planned submission to allow EMA to plan resources and appoint rapporteurs.,0
56,15,Preparation of the pre-submission meeting with Rapporteurs,Global Regulatory Lead,180,70,80,90,Y,75.0,Preparation for the pre-submission meeting with EMA Rapporteurs typically held about 3 months after the eligibility request and ~3 months before submission. This meeting aims to discuss the MAA content address specific regulatory requirements and review key documents such as the draft SmPC to ensure alignment before dossier submission.,0
57,15,Preparation of the pre-submission meeting with Rapporteurs,Labeling,180,70,80,90,Y,70.0,Preparation for the pre-submission meeting with EMA Rapporteurs typically held about 3 months after the eligibility request and ~3 months before submission. This meeting aims to discuss the MAA content address specific regulatory requirements and review key documents such as the draft SmPC to ensure alignment before dossier submission.,0
58,15,Preparation of the pre-submission meeting with Rapporteurs,Other function,180,70,80,90,Y,70.0,Preparation for the pre-submission meeting with EMA Rapporteurs typically held about 3 months after the eligibility request and ~3 months before submission. This meeting aims to discuss the MAA content address specific regulatory requirements and review key documents such as the draft SmPC to ensure alignment before dossier submission.,0
59,15,Preparation of the pre-submission meeting with Rapporteurs,Regulatory CMC,180,70,80,90,Y,70.0,Preparation for the pre-submission meeting with EMA Rapporteurs typically held about 3 months after the eligibility request and ~3 months before submission. This meeting aims to discuss the MAA content address specific regulatory requirements and review key documents such as the draft SmPC to ensure alignment before dossier submission.,0
60,15,Preparation of the pre-submission meeting with Rapporteurs,Regulatory Operations,180,70,80,90,Y,70.0,Preparation for the pre-submission meeting with EMA Rapporteurs typically held about 3 months after the eligibility request and ~3 months before submission. This meeting aims to discuss the MAA content address specific regulatory requirements and review key documents such as the draft SmPC to ensure alignment before dossier submission.,0
61,15,Preparation of the pre-submission meeting with Rapporteurs,Regulatory Strategist (Global/EU),180,70,80,90,Y,80.0,Preparation for the pre-submission meeting with EMA Rapporteurs typically held about 3 months after the eligibility request and ~3 months before submission. This meeting aims to discuss the MAA content address specific regulatory requirements and review key documents such as the draft SmPC to ensure alignment before dossier submission.,0
62,16,Pre-submission meeting with Rapporteurs Request,Global Regulatory Lead,185,2,2,2,Y,1.0,Formal request to EMA for a pre-submission meeting with the appointed Rapporteurs usually submitted around 6 months before the planned MAA submission. This request initiates the scheduling of the meeting to discuss dossier content regulatory expectations and any product-specific requirements.,0
63,16,Pre-submission meeting with Rapporteurs Request,Labeling,185,2,2,2,Y,1.0,Formal request to EMA for a pre-submission meeting with the appointed Rapporteurs usually submitted around 6 months before the planned MAA submission. This request initiates the scheduling of the meeting to discuss dossier content regulatory expectations and any product-specific requirements.,0
64,16,Pre-submission meeting with Rapporteurs Request,Regulatory CMC,185,2,2,2,Y,1.0,Formal request to EMA for a pre-submission meeting with the appointed Rapporteurs usually submitted around 6 months before the planned MAA submission. This request initiates the scheduling of the meeting to discuss dossier content regulatory expectations and any product-specific requirements.,0
65,16,Pre-submission meeting with Rapporteurs Request,Regulatory Operations,185,2,2,2,Y,1.0,Formal request to EMA for a pre-submission meeting with the appointed Rapporteurs usually submitted around 6 months before the planned MAA submission. This request initiates the scheduling of the meeting to discuss dossier content regulatory expectations and any product-specific requirements.,0
66,16,Pre-submission meeting with Rapporteurs Request,Regulatory Strategist (Global/EU),185,2,2,2,Y,5.0,Formal request to EMA for a pre-submission meeting with the appointed Rapporteurs usually submitted around 6 months before the planned MAA submission. This request initiates the scheduling of the meeting to discuss dossier content regulatory expectations and any product-specific requirements.,0
67,17,EMA pre-submission meeting,Global Regulatory Lead,90,1,1,1,Y,1.0,Official pre-submission meeting with EMA Rapporteurs usually scheduled about 3 months before the planned submission. Its purpose is to review the overall MAA package clarify regulatory expectations and ensure readiness for validation and assessment.,1
68,17,EMA pre-submission meeting,Labeling,90,1,1,1,Y,1.0,Official pre-submission meeting with EMA Rapporteurs usually scheduled about 3 months before the planned submission. Its purpose is to review the overall MAA package clarify regulatory expectations and ensure readiness for validation and assessment.,1
69,17,EMA pre-submission meeting,Other function,90,1,1,1,Y,1.0,Official pre-submission meeting with EMA Rapporteurs usually scheduled about 3 months before the planned submission. Its purpose is to review the overall MAA package clarify regulatory expectations and ensure readiness for validation and assessment.,1
70,17,EMA pre-submission meeting,Regulatory CMC,90,1,1,1,Y,1.0,Official pre-submission meeting with EMA Rapporteurs usually scheduled about 3 months before the planned submission. Its purpose is to review the overall MAA package clarify regulatory expectations and ensure readiness for validation and assessment.,1
71,17,EMA pre-submission meeting,Regulatory Operations,90,1,1,1,Y,1.0,Official pre-submission meeting with EMA Rapporteurs usually scheduled about 3 months before the planned submission. Its purpose is to review the overall MAA package clarify regulatory expectations and ensure readiness for validation and assessment.,1
72,17,EMA pre-submission meeting,Regulatory Strategist (Global/EU),90,1,1,1,Y,5.0,Official pre-submission meeting with EMA Rapporteurs usually scheduled about 3 months before the planned submission. Its purpose is to review the overall MAA package clarify regulatory expectations and ensure readiness for validation and assessment.,1
73,18,Orphan Drug Designation,Global Regulatory Lead,700,150,170,210,Y,36.0,“Manages PIP orphan drug status PRIME and compliance checkscommence avant le pip pendant phase 2 et se termine 3 mosi avant le PIP “,0
74,18,Orphan Drug Designation,Labeling,700,150,170,210,Y,30.0,“Manages PIP orphan drug status PRIME and compliance checks commence avant le pip pendant phase 2 et se termine 3 mosi avant le PIP “,0
75,18,Orphan Drug Designation,Other function,700,150,170,210,Y,30.0,“Manages PIP orphan drug status PRIME and compliance checks commence avant le pip pendant phase 2 et se termine 3 mosi avant le PIP “,0
76,18,Orphan Drug Designation,Regulatory CMC,700,150,170,210,Y,30.0,“Manages PIP orphan drug status PRIME and compliance checks commence avant le pip pendant phase 2 et se termine 3 mosi avant le PIP “,0
77,18,Orphan Drug Designation,Regulatory Operations,700,150,170,210,Y,30.0,“Manages PIP orphan drug status PRIME and compliance checks commence avant le pip pendant phase 2 et se termine 3 mosi avant le PIP “,0
78,18,Orphan Drug Designation,Regulatory Strategist (Global/EU),700,150,170,210,Y,36.0,“Manages PIP orphan drug status PRIME and compliance checks commence avant le pip pendant phase 2 et se termine 3 mosi avant le PIP “,0
79,19,Orphan Drug Designation granted,EMA,526,1,1,1,Y,1.0,“Manages PIP orphan drug status PRIME and compliance checks commence avant le pip pendant phase 2 et se termine 3 mosi avant le PIP “,1
58,13,Invented name (EMA NRG),Other function,300,84,90,98,Y,2.0,Submission of the invented name request to the EMA Name Review Group (NRG) ideally 12 months before the planned MAA submission. This step secures approval of the proposed product name which is mandatory for the MAA. In a worst-case scenario the request may still be accepted up to 4 months before submission.,0
59,13,Invented name (EMA NRG),Regulatory Operations,300,84,90,98,Y,2.0,Submission of the invented name request to the EMA Name Review Group (NRG) ideally 12 months before the planned MAA submission. This step secures approval of the proposed product name which is mandatory for the MAA. In a worst-case scenario the request may still be accepted up to 4 months before submission.,0
60,13,Invented name (EMA NRG),Regulatory Strategist (Global/EU),300,84,90,98,Y,4.0,Submission of the invented name request to the EMA Name Review Group (NRG) ideally 12 months before the planned MAA submission. This step secures approval of the proposed product name which is mandatory for the MAA. In a worst-case scenario the request may still be accepted up to 4 months before submission.,0
60,13,Invented name approval (EMA NRG),EMA,210,1,1,1,Y,2.0,Submission of the invented name request to the EMA Name Review Group (NRG) ideally 12 months before the planned MAA submission. This step secures approval of the proposed product name which is mandatory for the MAA. In a worst-case scenario the request may still be accepted up to 4 months before submission.,1
62,15,ATC code request ,Regulatory Strategist (Global/EU),300,70,80,90,Y,36.0,Submission of the ATC (Anatomical Therapeutic Chemical) code request to WHO required for the MAA dossier. Ideally submitted up to 12 months before the planned submission and no later than 3 months prior to ensure the product is assigned an official ATC classification in time for evaluation.,0
62,15,ATC code request ,Regulatory Operations,300,70,80,90,Y,6.0,Submission of the ATC (Anatomical Therapeutic Chemical) code request to WHO required for the MAA dossier. Ideally submitted up to 12 months before the planned submission and no later than 3 months prior to ensure the product is assigned an official ATC classification in time for evaluation.,0
62,15,ATC code request submitted,Regulatory Strategist (Global/EU),230,1,1,1,Y,36.0,Submission of the ATC (Anatomical Therapeutic Chemical) code request to WHO required for the MAA dossier. Ideally submitted up to 12 months before the planned submission and no later than 3 months prior to ensure the product is assigned an official ATC classification in time for evaluation.,1
63,16,Final nonclinical pharmacology study report,Other function,550,159,159,159,Y,0.2,Provides definitive nonclinical pharmacology results for efficacy and safety assessment,0
64,17,Final nonclinical pharmacokinetic study report,Other function,550,159,159,159,Y,0.2,Provides final nonclinical pharmacokinetic results,0
65,18,Final nonclinical toxicology study report,Other function,550,159,159,159,Y,0.2,Provides definitive nonclinical toxicology results for safety evaluation,0
66,19,Final clinical study report (last pivotal study),Other function,450,288,288,288,Y,0.2,Provides final report for the last pivotal clinical study,0
67,20,Population PK analysis report,Regulatory Operations,450,288,288,288,Y,12.0,Provides population pharmacokinetic analysis across clinical studies,0
68,21,Integrated Summary of Safety (ISS),Global Regulatory Lead,400,350,350,350,Y,12.0,Summarises safety findings across clinical studies,0
69,21,Integrated Summary of Safety (ISS),Labeling,400,350,350,350,Y,12.0,Summarises safety findings across clinical studies,0
70,21,Integrated Summary of Safety (ISS),Other function,400,350,350,350,Y,12.0,Summarises safety findings across clinical studies,0
71,21,Integrated Summary of Safety (ISS),Regulatory Operations,400,350,350,350,Y,12.0,Summarises safety findings across clinical studies,0
72,21,Integrated Summary of Safety (ISS),Regulatory Strategist (Global/EU),400,350,350,350,Y,12.0,Summarises safety findings across clinical studies,0
73,22,Integrated Summary of Efficacy (ISE),Global Regulatory Lead,400,350,350,350,Y,12.0,Summarises efficacy findings across clinical studies,0
74,22,Integrated Summary of Efficacy (ISE),Labeling,400,350,350,350,Y,12.0,Summarises efficacy findings across clinical studies,0
75,22,Integrated Summary of Efficacy (ISE),Other function,400,350,350,350,Y,12.0,Summarises efficacy findings across clinical studies,0
76,22,Integrated Summary of Efficacy (ISE),Regulatory Operations,400,350,350,350,Y,12.0,Summarises efficacy findings across clinical studies,0
77,22,Integrated Summary of Efficacy (ISE),Regulatory Strategist (Global/EU),400,350,350,350,Y,12.0,Summarises efficacy findings across clinical studies,0
78,23,Integrated Summary of Immunogenicity,Global Regulatory Lead,400,350,350,350,Y,6.0,Summarises clinical immunogenicity across studies,0
79,23,Integrated Summary of Immunogenicity,Labeling,400,350,350,350,Y,6.0,Summarises clinical immunogenicity across studies,0
80,23,Integrated Summary of Immunogenicity,Other function,400,350,350,350,Y,6.0,Summarises clinical immunogenicity across studies,0
81,23,Integrated Summary of Immunogenicity,Regulatory Operations,400,350,350,350,Y,6.0,Summarises clinical immunogenicity across studies,0
82,23,Integrated Summary of Immunogenicity,Regulatory Strategist (Global/EU),400,350,350,350,Y,6.0,Summarises clinical immunogenicity across studies,0
83,24,Summary of Biopharmaceutic Studies (Module 2.7.1),Global Regulatory Lead,400,350,350,350,Y,3.0,Summarises bioavailability and bioequivalence evidence,0
84,24,Summary of Biopharmaceutic Studies (Module 2.7.1),Labeling,400,350,350,350,Y,3.0,Summarises bioavailability and bioequivalence evidence,0
85,24,Summary of Biopharmaceutic Studies (Module 2.7.1),Other function,400,350,350,350,Y,3.0,Summarises bioavailability and bioequivalence evidence,0
86,24,Summary of Biopharmaceutic Studies (Module 2.7.1),Regulatory Operations,400,350,350,350,Y,3.0,Summarises bioavailability and bioequivalence evidence,0
87,24,Summary of Biopharmaceutic Studies (Module 2.7.1),Regulatory Strategist (Global/EU),400,350,350,350,Y,3.0,Summarises bioavailability and bioequivalence evidence,0
88,25,Summary of Clinical Pharmacology (Module 2.7.2),Global Regulatory Lead,400,350,350,350,Y,6.0,Summarises clinical pharmacology including PK and PD,0
89,25,Summary of Clinical Pharmacology (Module 2.7.2),Labeling,400,350,350,350,Y,6.0,Summarises clinical pharmacology including PK and PD,0
90,25,Summary of Clinical Pharmacology (Module 2.7.2),Other function,400,350,350,350,Y,6.0,Summarises clinical pharmacology including PK and PD,0
91,25,Summary of Clinical Pharmacology (Module 2.7.2),Regulatory Operations,400,350,350,350,Y,6.0,Summarises clinical pharmacology including PK and PD,0
92,25,Summary of Clinical Pharmacology (Module 2.7.2),Regulatory Strategist (Global/EU),400,350,350,350,Y,6.0,Summarises clinical pharmacology including PK and PD,0
93,26,Summary of Clinical Efficacy (Module 2.7.3),Global Regulatory Lead,400,350,350,350,Y,9.0,Presents integrated clinical efficacy summary,0
94,26,Summary of Clinical Efficacy (Module 2.7.3),Labeling,400,350,350,350,Y,9.0,Presents integrated clinical efficacy summary,0
95,26,Summary of Clinical Efficacy (Module 2.7.3),Other function,400,350,350,350,Y,9.0,Presents integrated clinical efficacy summary,0
96,26,Summary of Clinical Efficacy (Module 2.7.3),Regulatory Operations,400,350,350,350,Y,9.0,Presents integrated clinical efficacy summary,0
97,26,Summary of Clinical Efficacy (Module 2.7.3),Regulatory Strategist (Global/EU),400,350,350,350,Y,9.0,Presents integrated clinical efficacy summary,0
98,27,Summary of Clinical Safety (Module 2.7.4),Global Regulatory Lead,400,350,350,350,Y,9.0,Presents integrated clinical safety summary,0
99,27,Summary of Clinical Safety (Module 2.7.4),Labeling,400,350,350,350,Y,9.0,Presents integrated clinical safety summary,0
100,27,Summary of Clinical Safety (Module 2.7.4),Other function,400,350,350,350,Y,9.0,Presents integrated clinical safety summary,0
101,27,Summary of Clinical Safety (Module 2.7.4),Regulatory Operations,400,350,350,350,Y,9.0,Presents integrated clinical safety summary,0
102,27,Summary of Clinical Safety (Module 2.7.4),Regulatory Strategist (Global/EU),400,350,350,350,Y,9.0,Presents integrated clinical safety summary,0
103,28,Clinical Overview (Module 2.5),Global Regulatory Lead,400,350,350,350,Y,6.0,Provides high level clinical assessment and benefit risk,0
104,28,Clinical Overview (Module 2.5),Labeling,400,350,350,350,Y,6.0,Provides high level clinical assessment and benefit risk,0
105,28,Clinical Overview (Module 2.5),Other function,400,350,350,350,Y,6.0,Provides high level clinical assessment and benefit risk,0
106,28,Clinical Overview (Module 2.5),Regulatory Operations,400,350,350,350,Y,6.0,Provides high level clinical assessment and benefit risk,0
107,28,Clinical Overview (Module 2.5),Regulatory Strategist (Global/EU),400,350,350,350,Y,6.0,Provides high level clinical assessment and benefit risk,0
108,29,Clinical literature references compiled (Module 2.7.5),Labeling,400,350,350,350,Y,3.0,Collects clinical literature citations for module two,0
109,30,Clinical study synopses finalized (Module 2.7.6),Regulatory Strategist (Global/EU),400,350,350,350,Y,2.0,Finalises ICH E3 study synopses for module two,0
110,31,Nonclinical Introduction (Module 2.6.1),Global Regulatory Lead,400,288,288,288,Y,0.4,Introduces scope of nonclinical summaries,0
111,31,Nonclinical Introduction (Module 2.6.1),Other function,400,288,288,288,Y,0.4,Introduces scope of nonclinical summaries,0
112,31,Nonclinical Introduction (Module 2.6.1),Regulatory Operations,400,288,288,288,Y,0.4,Introduces scope of nonclinical summaries,0
113,31,Nonclinical Introduction (Module 2.6.1),Regulatory Strategist (Global/EU),400,288,288,288,Y,0.4,Introduces scope of nonclinical summaries,0
114,32,Nonclinical Written Summary – Pharmacology (Module 2.6.2),Regulatory Strategist (Global/EU),400,288,288,288,Y,3.0,Summarises primary and secondary pharmacology,0
115,33,Nonclinical Tabulated Summary – Pharmacology (Module 2.6.3),Regulatory Strategist (Global/EU),400,288,288,288,Y,2.0,Provides tabulated pharmacology data,0
116,34,Nonclinical Written Summary – Pharmacokinetics (Module 2.6.4),Regulatory Strategist (Global/EU),400,288,288,288,Y,3.0,Summarises absorption distribution metabolism and excretion,0
117,35,Nonclinical Tabulated Summary – Pharmacokinetics (Module 2.6.5),Regulatory Strategist (Global/EU),400,288,288,288,Y,2.0,Provides tabulated pharmacokinetic data,0
118,36,Nonclinical Written Summary – Toxicology (Module 2.6.6),Regulatory Strategist (Global/EU),400,288,288,288,Y,6.0,Summarises toxicology findings and safety margins,0
119,37,Nonclinical Tabulated Summary – Toxicology (Module 2.6.7),Regulatory Strategist (Global/EU),400,288,288,288,Y,3.0,Provides tabulated toxicology data,0
120,38,Nonclinical Overview (Module 2.4),Global Regulatory Lead,400,288,288,288,Y,6.0,Provides overall interpretation of nonclinical program,0
121,38,Nonclinical Overview (Module 2.4),Other function,400,288,288,288,Y,6.0,Provides overall interpretation of nonclinical program,0
122,38,Nonclinical Overview (Module 2.4),Regulatory Operations,400,288,288,288,Y,6.0,Provides overall interpretation of nonclinical program,0
123,38,Nonclinical Overview (Module 2.4),Regulatory Strategist (Global/EU),400,288,288,288,Y,6.0,Provides overall interpretation of nonclinical program,0
124,39,Nonclinical literature references compiled (Module 4.3),Regulatory Strategist (Global/EU),450,288,280,280,Y,1.0,Collects nonclinical literature citations for module four,0
125,40,GMP Clearance (for manufacturing sites),Other function,150,120,120,120,Y,18.0,Confirms EU GMP compliance of manufacturing sites,0
126,40,GMP Clearance (for manufacturing sites),Regulatory CMC,150,120,120,120,Y,18.0,Confirms EU GMP compliance of manufacturing sites,0
127,40,GMP Clearance (for manufacturing sites),Regulatory Operations,150,120,120,120,Y,18.0,Confirms EU GMP compliance of manufacturing sites,0
128,40,GMP Clearance (for manufacturing sites),Regulatory Strategist (Global/EU),150,120,120,120,Y,18.0,Confirms EU GMP compliance of manufacturing sites,0
129,41,GMP Certificates (from manufacturing sites),Other function,150,120,120,120,Y,18.0,Collects valid GMP certificates from authorities,0
130,41,GMP Certificates (from manufacturing sites),Regulatory CMC,150,120,120,120,Y,18.0,Collects valid GMP certificates from authorities,0
131,41,GMP Certificates (from manufacturing sites),Regulatory Operations,150,120,120,120,Y,18.0,Collects valid GMP certificates from authorities,0
132,41,GMP Certificates (from manufacturing sites),Regulatory Strategist (Global/EU),150,120,120,120,Y,18.0,Collects valid GMP certificates from authorities,0
133,42,Manufacturing Authorisations collected,Regulatory Operations,150,120,120,120,Y,6.0,Collects manufacturing authorisations for sites,0
134,43,Manufacturing Process Flow Chart completed,Regulatory Operations,450,350,350,350,Y,"2.8""",Documents process flow for drug product and substance,0
135,44,3.2.S.1 Drug Substance: General Information section,Labeling,450,350,350,350,Y,2.0,Describes substance nomenclature and structure,0
136,44,3.2.S.1 Drug Substance: General Information section,Other function,450,350,350,350,Y,2.0,Describes substance nomenclature and structure,0
137,44,3.2.S.1 Drug Substance: General Information section,Regulatory CMC,450,350,350,350,Y,2.0,Describes substance nomenclature and structure,0
138,44,3.2.S.1 Drug Substance: General Information section,Regulatory Operations,450,350,350,350,Y,2.0,Describes substance nomenclature and structure,0
139,44,3.2.S.1 Drug Substance: General Information section,Regulatory Strategist (Global/EU),450,350,350,350,Y,2.0,Describes substance nomenclature and structure,0
140,45,3.2.S.2 Drug Substance: Manufacture section,Labeling,450,350,350,350,Y,9.0,Describes manufacturers and process controls,0
141,45,3.2.S.2 Drug Substance: Manufacture section,Other function,450,350,350,350,Y,9.0,Describes manufacturers and process controls,0
142,45,3.2.S.2 Drug Substance: Manufacture section,Regulatory CMC,450,350,350,350,Y,9.0,Describes manufacturers and process controls,0
143,45,3.2.S.2 Drug Substance: Manufacture section,Regulatory Operations,450,350,350,350,Y,9.0,Describes manufacturers and process controls,0
144,45,3.2.S.2 Drug Substance: Manufacture section,Regulatory Strategist (Global/EU),450,350,350,350,Y,9.0,Describes manufacturers and process controls,0
145,46,3.2.S.3 Drug Substance: Characterisation section,Labeling,450,350,350,350,Y,6.0,Details physicochemical and biological characterisation,0
146,46,3.2.S.3 Drug Substance: Characterisation section,Other function,450,350,350,350,Y,6.0,Details physicochemical and biological characterisation,0
147,46,3.2.S.3 Drug Substance: Characterisation section,Regulatory CMC,450,350,350,350,Y,6.0,Details physicochemical and biological characterisation,0
148,46,3.2.S.3 Drug Substance: Characterisation section,Regulatory Operations,450,350,350,350,Y,6.0,Details physicochemical and biological characterisation,0
149,46,3.2.S.3 Drug Substance: Characterisation section,Regulatory Strategist (Global/EU),450,350,350,350,Y,6.0,Details physicochemical and biological characterisation,0
150,47,3.2.S.4 Drug Substance: Control of Drug Substance section,Labeling,450,350,350,350,Y,9.0,Describes specifications and analytical methods,0
151,47,3.2.S.4 Drug Substance: Control of Drug Substance section,Other function,450,350,350,350,Y,9.0,Describes specifications and analytical methods,0
152,47,3.2.S.4 Drug Substance: Control of Drug Substance section,Regulatory CMC,450,350,350,350,Y,9.0,Describes specifications and analytical methods,0
153,47,3.2.S.4 Drug Substance: Control of Drug Substance section,Regulatory Operations,450,350,350,350,Y,9.0,Describes specifications and analytical methods,0
154,47,3.2.S.4 Drug Substance: Control of Drug Substance section,Regulatory Strategist (Global/EU),450,350,350,350,Y,9.0,Describes specifications and analytical methods,0
155,48,3.2.S.5 Drug Substance: Reference Standards section,Labeling,450,350,350,350,Y,1.4,Describes reference standards and materials,0
156,48,3.2.S.5 Drug Substance: Reference Standards section,Other function,450,350,350,350,Y,1.4,Describes reference standards and materials,0
157,48,3.2.S.5 Drug Substance: Reference Standards section,Regulatory CMC,450,350,350,350,Y,1.4,Describes reference standards and materials,0
158,48,3.2.S.5 Drug Substance: Reference Standards section,Regulatory Operations,450,350,350,350,Y,1.4,Describes reference standards and materials,0
159,48,3.2.S.5 Drug Substance: Reference Standards section,Regulatory Strategist (Global/EU),450,350,350,350,Y,1.4,Describes reference standards and materials,0
160,49,3.2.S.6 Drug Substance: Container Closure System section,Labeling,450,350,350,350,Y,1.4,Describes container closure for substance,0
161,49,3.2.S.6 Drug Substance: Container Closure System section,Other function,450,350,350,350,Y,1.4,Describes container closure for substance,0
162,49,3.2.S.6 Drug Substance: Container Closure System section,Regulatory CMC,450,350,350,350,Y,1.4,Describes container closure for substance,0
163,49,3.2.S.6 Drug Substance: Container Closure System section,Regulatory Operations,450,350,350,350,Y,1.4,Describes container closure for substance,0
164,49,3.2.S.6 Drug Substance: Container Closure System section,Regulatory Strategist (Global/EU),450,350,350,350,Y,1.4,Describes container closure for substance,0
165,50,3.2.S.7 Drug Substance: Stability section,Labeling,450,350,350,350,Y,6.0,Presents stability data and conclusions,0
166,50,3.2.S.7 Drug Substance: Stability section,Other function,450,350,350,350,Y,6.0,Presents stability data and conclusions,0
167,50,3.2.S.7 Drug Substance: Stability section,Regulatory CMC,450,350,350,350,Y,6.0,Presents stability data and conclusions,0
168,50,3.2.S.7 Drug Substance: Stability section,Regulatory Operations,450,350,350,350,Y,6.0,Presents stability data and conclusions,0
169,50,3.2.S.7 Drug Substance: Stability section,Regulatory Strategist (Global/EU),450,350,350,350,Y,6.0,Presents stability data and conclusions,0
170,51,3.2.P.1 Drug Product: Description and Composition section,Labeling,450,350,350,350,Y,1.4,Describes composition and presentation of product,0
171,51,3.2.P.1 Drug Product: Description and Composition section,Other function,450,350,350,350,Y,1.4,Describes composition and presentation of product,0
172,51,3.2.P.1 Drug Product: Description and Composition section,Regulatory CMC,450,350,350,350,Y,1.4,Describes composition and presentation of product,0
173,51,3.2.P.1 Drug Product: Description and Composition section,Regulatory Operations,450,350,350,350,Y,1.4,Describes composition and presentation of product,0
174,51,3.2.P.1 Drug Product: Description and Composition section,Regulatory Strategist (Global/EU),450,350,350,350,Y,1.4,Describes composition and presentation of product,0
175,52,3.2.P.2 Drug Product: Pharmaceutical Development section,Labeling,450,350,350,350,Y,12.0,Justifies formulation and manufacturing development,0
176,52,3.2.P.2 Drug Product: Pharmaceutical Development section,Other function,450,350,350,350,Y,12.0,Justifies formulation and manufacturing development,0
177,52,3.2.P.2 Drug Product: Pharmaceutical Development section,Regulatory CMC,450,350,350,350,Y,12.0,Justifies formulation and manufacturing development,0
178,52,3.2.P.2 Drug Product: Pharmaceutical Development section,Regulatory Operations,450,350,350,350,Y,12.0,Justifies formulation and manufacturing development,0
179,52,3.2.P.2 Drug Product: Pharmaceutical Development section,Regulatory Strategist (Global/EU),450,350,350,350,Y,12.0,Justifies formulation and manufacturing development,0
180,53,3.2.P.3 Drug Product: Manufacture section,Labeling,450,350,350,350,Y,6.0,Describes manufacturing process and controls,0
181,53,3.2.P.3 Drug Product: Manufacture section,Other function,450,350,350,350,Y,6.0,Describes manufacturing process and controls,0
182,53,3.2.P.3 Drug Product: Manufacture section,Regulatory CMC,450,350,350,350,Y,6.0,Describes manufacturing process and controls,0
183,53,3.2.P.3 Drug Product: Manufacture section,Regulatory Operations,450,350,350,350,Y,6.0,Describes manufacturing process and controls,0
184,53,3.2.P.3 Drug Product: Manufacture section,Regulatory Strategist (Global/EU),450,350,350,350,Y,6.0,Describes manufacturing process and controls,0
185,54,3.2.P.4 Drug Product: Control of Excipients section,Labeling,450,350,350,350,Y,2.0,Describes excipient specifications and quality,0
186,54,3.2.P.4 Drug Product: Control of Excipients section,Other function,450,350,350,350,Y,2.0,Describes excipient specifications and quality,0
187,54,3.2.P.4 Drug Product: Control of Excipients section,Regulatory CMC,450,350,350,350,Y,2.0,Describes excipient specifications and quality,0
188,54,3.2.P.4 Drug Product: Control of Excipients section,Regulatory Operations,450,350,350,350,Y,2.0,Describes excipient specifications and quality,0
189,54,3.2.P.4 Drug Product: Control of Excipients section,Regulatory Strategist (Global/EU),450,350,350,350,Y,2.0,Describes excipient specifications and quality,0
190,55,3.2.P.5 Drug Product: Control of Drug Product section,Labeling,450,350,350,350,Y,9.0,Defines product specifications and methods,0
191,55,3.2.P.5 Drug Product: Control of Drug Product section,Other function,450,350,350,350,Y,9.0,Defines product specifications and methods,0
192,55,3.2.P.5 Drug Product: Control of Drug Product section,Regulatory CMC,450,350,350,350,Y,9.0,Defines product specifications and methods,0
193,55,3.2.P.5 Drug Product: Control of Drug Product section,Regulatory Operations,450,350,350,350,Y,9.0,Defines product specifications and methods,0
194,55,3.2.P.5 Drug Product: Control of Drug Product section,Regulatory Strategist (Global/EU),450,350,350,350,Y,9.0,Defines product specifications and methods,0
195,56,3.2.P.6 Drug Product: Reference Standards section,Labeling,450,350,350,350,Y,1.0,Describes product reference standards,0
196,56,3.2.P.6 Drug Product: Reference Standards section,Other function,450,350,350,350,Y,1.0,Describes product reference standards,0
197,56,3.2.P.6 Drug Product: Reference Standards section,Regulatory CMC,450,350,350,350,Y,1.0,Describes product reference standards,0
198,56,3.2.P.6 Drug Product: Reference Standards section,Regulatory Operations,450,350,350,350,Y,1.0,Describes product reference standards,0
199,56,3.2.P.6 Drug Product: Reference Standards section,Regulatory Strategist (Global/EU),450,350,350,350,Y,1.0,Describes product reference standards,0
200,57,3.2.P.7 Drug Product: Container Closure System section,Labeling,450,350,350,350,Y,1.4,Describes container closure for product,0
201,57,3.2.P.7 Drug Product: Container Closure System section,Other function,450,350,350,350,Y,1.4,Describes container closure for product,0
202,57,3.2.P.7 Drug Product: Container Closure System section,Regulatory CMC,450,350,350,350,Y,1.4,Describes container closure for product,0
203,57,3.2.P.7 Drug Product: Container Closure System section,Regulatory Operations,450,350,350,350,Y,1.4,Describes container closure for product,0
204,57,3.2.P.7 Drug Product: Container Closure System section,Regulatory Strategist (Global/EU),450,350,350,350,Y,1.4,Describes container closure for product,0
205,58,3.2.P.8 Drug Product: Stability section,Labeling,450,350,350,350,Y,6.0,Presents product stability data and conclusions,0
206,58,3.2.P.8 Drug Product: Stability section,Other function,450,350,350,350,Y,6.0,Presents product stability data and conclusions,0
207,58,3.2.P.8 Drug Product: Stability section,Regulatory CMC,450,350,350,350,Y,6.0,Presents product stability data and conclusions,0
208,58,3.2.P.8 Drug Product: Stability section,Regulatory Operations,450,350,350,350,Y,6.0,Presents product stability data and conclusions,0
209,58,3.2.P.8 Drug Product: Stability section,Regulatory Strategist (Global/EU),450,350,350,350,Y,6.0,Presents product stability data and conclusions,0
210,59,3.2.A.1 Appendices: Facilities and Equipment,Labeling,450,350,350,350,Y,2.8,Provides facility and equipment descriptions,0
211,59,3.2.A.1 Appendices: Facilities and Equipment,Other function,450,350,350,350,Y,2.8,Provides facility and equipment descriptions,0
212,59,3.2.A.1 Appendices: Facilities and Equipment,Regulatory CMC,450,350,350,350,Y,2.8,Provides facility and equipment descriptions,0
213,59,3.2.A.1 Appendices: Facilities and Equipment,Regulatory Operations,450,350,350,350,Y,2.8,Provides facility and equipment descriptions,0
214,59,3.2.A.1 Appendices: Facilities and Equipment,Regulatory Strategist (Global/EU),450,350,350,350,Y,2.8,Provides facility and equipment descriptions,0
215,60,3.2.A.2 Appendices: Adventitious Agents Safety,Labeling,450,350,350,350,Y,6.0,Assesses adventitious agent safety controls,0
216,60,3.2.A.2 Appendices: Adventitious Agents Safety,Other function,450,350,350,350,Y,6.0,Assesses adventitious agent safety controls,0
217,60,3.2.A.2 Appendices: Adventitious Agents Safety,Regulatory CMC,450,350,350,350,Y,6.0,Assesses adventitious agent safety controls,0
218,60,3.2.A.2 Appendices: Adventitious Agents Safety,Regulatory Operations,450,350,350,350,Y,6.0,Assesses adventitious agent safety controls,0
219,60,3.2.A.2 Appendices: Adventitious Agents Safety,Regulatory Strategist (Global/EU),450,350,350,350,Y,6.0,Assesses adventitious agent safety controls,0
220,61,3.2.R Regional Information section completed,Labeling,450,350,350,350,Y,2.0,Includes regional European quality information,0
221,61,3.2.R Regional Information section completed,Other function,450,350,350,350,Y,2.0,Includes regional European quality information,0
222,61,3.2.R Regional Information section completed,Regulatory CMC,450,350,350,350,Y,2.0,Includes regional European quality information,0
223,61,3.2.R Regional Information section completed,Regulatory Operations,450,350,350,350,Y,2.0,Includes regional European quality information,0
224,61,3.2.R Regional Information section completed,Regulatory Strategist (Global/EU),450,350,350,350,Y,2.0,Includes regional European quality information,0
225,62,Quality Overall Summary – Introduction (Module 2.3.1),Regulatory Strategist (Global/EU),400,350,350,350,Y,0.6,Introduces quality overall summary structure,0
226,63,Quality Overall Summary – Drug Substance (Module 2.3.S),Regulatory Strategist (Global/EU),400,350,350,350,Y,3.0,Summarises quality information for substance,0
227,64,Quality Overall Summary – Drug Product (Module 2.3.P),Regulatory Strategist (Global/EU),400,350,350,350,Y,3.0,Summarises quality information for product,0
228,65,Quality Overall Summary – Appendices (Module 2.3.A),Regulatory Strategist (Global/EU),400,350,350,350,Y,1.0,Summarises quality appendices content,0
229,66,Quality Overall Summary – Regional Information (Module 2.3.R),Regulatory Strategist (Global/EU),400,350,350,350,Y,1.0,Summarises quality regional information,0
230,67,Company Core Data Sheet (CCDS) finalized,Regulatory Operations,700,600,640,650,Y,12.0,Company core data sheet is finalized aligned with global labeling and serves as the reference for SmPC and PI,0
231,68,Risk Management Plan (RMP),Labeling,150,120,120,120,Y,12.0,Risk management plan is prepared reviewed and finalized with mitigation measures defined and endorsed,0
232,68,Risk Management Plan (RMP),Other function,150,120,120,120,Y,12.0,Risk management plan is prepared reviewed and finalized with mitigation measures defined and endorsed,0
233,68,Risk Management Plan (RMP),Regulatory Operations,150,120,120,120,Y,12.0,Risk management plan is prepared reviewed and finalized with mitigation measures defined and endorsed,0
234,68,Risk Management Plan (RMP),Regulatory Strategist (Global/EU),150,120,120,120,Y,12.0,Risk management plan is prepared reviewed and finalized with mitigation measures defined and endorsed,0
235,69,EU SmPC (Product Information) draft,Regulatory Strategist (Global/EU),150,120,120,120,Y,9.0,Draft SmPC is prepared based on CCDS and aligned with EMA guidance before final review,0
88,24,Messaging alignment meeting 1,Global Regulatory Lead,420,1,1,1,Y,1.2,Cross functional alignment meeting ensures consistency of key regulatory and scientific messages,1
88,24,Messaging alignment meeting 1,Management,420,1,1,1,Y,1.2,Cross functional alignment meeting ensures consistency of key regulatory and scientific messages,1
89,24,Messaging alignment meeting 1,Labeling,420,1,1,1,Y,0.2,Cross functional alignment meeting ensures consistency of key regulatory and scientific messages,1
90,24,Messaging alignment meeting 1,Other function,420,1,1,1,Y,0.2,Cross functional alignment meeting ensures consistency of key regulatory and scientific messages,1
91,24,Messaging alignment meeting 1,Regulatory CMC,420,1,1,1,Y,0.2,Cross functional alignment meeting ensures consistency of key regulatory and scientific messages,1
92,24,Messaging alignment meeting 1,Regulatory Strategist (Global/EU),420,1,1,1,Y,0.2,Cross functional alignment meeting ensures consistency of key regulatory and scientific messages,1
93,25,Messaging alignment meeting 2,Global Regulatory Lead,300,1,1,1,Y,1.2,Cross functional alignment meeting ensures consistency of key regulatory and scientific messages,1
94,25,Messaging alignment meeting 2,Labeling,300,1,1,1,Y,0.2,Cross functional alignment meeting ensures consistency of key regulatory and scientific messages,1
95,25,Messaging alignment meeting 2,Other function,300,1,1,1,Y,0.2,Cross functional alignment meeting ensures consistency of key regulatory and scientific messages,1
96,25,Messaging alignment meeting 2,Regulatory CMC,300,1,1,1,Y,0.2,Cross functional alignment meeting ensures consistency of key regulatory and scientific messages,1
97,25,Messaging alignment meeting 2,Regulatory Operations,300,1,1,1,Y,0.2,Cross functional alignment meeting ensures consistency of key regulatory and scientific messages,1
98,25,Messaging alignment meeting 2,Regulatory Strategist (Global/EU),300,1,1,1,Y,0.2,Cross functional alignment meeting ensures consistency of key regulatory and scientific messages,1
247,72,Application Form (eAF) completed,Regulatory Strategist (Global/EU),180,159,159,159,Y,5.6,Electronic application form is completed validated and ready for inclusion in the submission package,0
248,73,Cover Letter for MAA submission,Regulatory Operations,180,159,159,159,Y,1.0,Cover letter is drafted finalized and prepared for inclusion in the MAA submission sequence,0
249,73,Cover Letter for MAA submission,Regulatory Strategist (Global/EU),180,159,159,159,Y,1.0,Cover letter is drafted finalized and prepared for inclusion in the MAA submission sequence,0
99,26,Product Artwork and Mock-ups,Labeling,130,109,109,109,Y,6.0,Product artwork and mock ups are developed checked and approved in line with CCDS and QRD templates,0
99,26,Product Artwork and Mock-ups,Regulatory Strategist (Global/EU),130,109,109,109,Y,6.0,Product artwork and mock ups are developed checked and approved in line with CCDS and QRD templates,0
99,26,Product Artwork and Mock-ups,Other function,130,109,109,109,Y,6.0,Product artwork and mock ups are developed checked and approved in line with CCDS and QRD templates,0
100,27,Compilation of eCTD dossier,Regulatory Operations,130,99,99,99,Y,2.8,Full eCTD sequence is compiled validated and prepared for submission according to technical standards,0
101,28,Final internal review and sign-off,Global Regulatory Lead,31,5,5,5,Y,4.4,Final quality control and internal sign off are performed before dispatch of the dossier,0
102,28,Final internal review and sign-off,Labeling,31,5,5,5,Y,0.4,Final quality control and internal sign off are performed before dispatch of the dossier,0
103,28,Final internal review and sign-off,Other function,31,5,5,5,Y,2.4,Final quality control and internal sign off are performed before dispatch of the dossier,0
104,28,Final internal review and sign-off,Regulatory CMC,31,5,5,5,Y,0.4,Final quality control and internal sign off are performed before dispatch of the dossier,0
105,28,Final internal review and sign-off,Regulatory Operations,31,5,5,5,Y,0.4,Final quality control and internal sign off are performed before dispatch of the dossier,0
105,28,Final internal review and sign-off,Regulatory Strategist (Global/EU),31,5,5,5,Y,0.4,Final quality control and internal sign off are performed before dispatch of the dossier,0
106,29,Validation of dispatch of MAA to EMA,Regulatory Operations,26,1,1,1,Y,2.0,Validation step confirms readiness of submission package five days before official dispatch,1
107,30,dispatch of MAA to EMA,Regulatory Operations,21,1,1,1,Y,0.2,Marketing authorisation application is officially dispatched to EMA as planned submission,1
108,31,EMA confirmation of submission receipt,EMA,0,1,1,1,Y,0.2,EMA confirms receipt of submission package approximately thirty days after dispatch,1